Cholangiocarcinoma — Trials

Cholangiocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

760 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 210
Recruiting: 120
Ph III recruiting: 7
Growth YoY: +17.4%
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (106)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06037980	CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence(PURITY)	recruiting	Phase 2 / Phase 3	300	Gruppo Oncologico del Nord-OvestOTHER	1	Sep 9, 2026	clinicaltrials
NCT06923475	Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma(NEODISCO)	recruiting	Phase 2 / Phase 3	150